<DOC>
	<DOCNO>NCT00101439</DOCNO>
	<brief_summary>A study evaluate cholesterol-lowering effect ezetimibe participant primary hypercholesterolemia ( high cholesterol ) eat meal high cholesterol . The primary hypothesis treatment ezetimibe 10 mg/day reduces cholesterol concentration chylomicron-containing Sfâ‰¥400 fraction follow cholesterol-enriched test meal .</brief_summary>
	<brief_title>A Study Evaluate Effects Ezetimibe ( MK-0653 ) Postprandial ( Following Meal ) Lipoprotein Response Participants With Primary Hypercholesterolemia ( High Cholesterol ) ( MK-0653-072 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Eligible patient otherwise healthy men woman ( oral contraceptive hormone replacement therapy ) 18 70 year age moderately high cholesterol . Individuals lipidlowering therapy ( medicine low cholesterol ) include statin ( within 6 week ) fibrates ( within 8 week ) prior administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Primary Hypercholesterolemia</keyword>
</DOC>